Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.

Background: Factor VIII (FVIII) replacement and emicizumab are effective at preventing bleeds in patients with hemophilia A (HA). Though benefits of emicizumab among inhibitor patients with HA (PwHA) are well established, more real-world evidence among non-inhibitor patients is needed.

Methods: Using a United States healthcare claims database, we compared billed annualized bleed rates (ABR) and the total cost of care (TCC) before and after switching from FVIII prophylaxis to emicizumab among non-inhibitor male PwHA.